Earnings ·
Xeris Biopharma Holdings reported second-quarter 2026 results with total revenue of $92.1 million, a 29% increase…
XERSXeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings reported second-quarter 2026 results with total revenue of $92.1 million, a 29% increase year-over-year, driven by an 81% surge in Recorlev net product revenue to approximately $57 million. Net product revenue grew 34% to $91 million, while Gvoke and Keveyis revenues remained relatively stable. The company reported a net loss of $31.1 million for the quarter, primarily due to a one-time non-cash charge of roughly $31 million related to fair value adjustments on its 2028 Convertible Notes exchange agreements. Adjusted EBITDA improved to $19.3 million from $12.5 million in the prior year period. Management tightened full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting confidence in commercial momentum and strategic investments. Xeris Biopharma operates in the biopharmaceutical industry, developing and commercializing innovative therapies for endocrine and rare diseases.